India To Set Up CRISPR Innovation Centre In Bengaluru
Technology

India To Set Up CRISPR Innovation Centre In Bengaluru

A new Letter of Intent has been signed to establish a Centre of Excellence for CRISPR Innovation and Translation, aimed at harnessing advanced CRISPR technologies to convert laboratory research into real-world clinical applications. The proposed centre will act as a dedicated hub to accelerate the translation of scientific discoveries into affordable and scalable healthcare solutions.

The Jawaharlal Nehru Centre for Advanced Scientific Research, Bengaluru—an autonomous institute under the Department of Science and Technology—and Delhi-based CrisprBits Private Limited have jointly announced the initiative, marking one of India’s early public–private partnerships in CRISPR-based biotechnology. CrisprBits specialises in gene-editing platforms focused on developing cost-effective diagnostic and therapeutic solutions.

The Centre of Excellence is envisioned as a bridge between fundamental research and clinical impact, combining JNCASR’s strengths in biomedical sciences with CrisprBits’ expertise in applied gene-editing and translational technologies. By addressing the long-standing gap between laboratory innovation and bedside application, the centre aims to demonstrate how Indian scientific research can be effectively transformed into societal and clinical benefits. It is also expected to serve as a replicable national model for strengthening collaboration between academia and industry within India’s biotechnology ecosystem.

Commenting on the development, JNCASR President Umesh Waghmare said the partnership represents a landmark step for the institution, bringing together complementary capabilities in genetics, molecular and chemical biology, and computational biology. He added that the collaboration would open new pathways to deliver societal impact while contributing to national scientific and innovation missions.

A new Letter of Intent has been signed to establish a Centre of Excellence for CRISPR Innovation and Translation, aimed at harnessing advanced CRISPR technologies to convert laboratory research into real-world clinical applications. The proposed centre will act as a dedicated hub to accelerate the translation of scientific discoveries into affordable and scalable healthcare solutions. The Jawaharlal Nehru Centre for Advanced Scientific Research, Bengaluru—an autonomous institute under the Department of Science and Technology—and Delhi-based CrisprBits Private Limited have jointly announced the initiative, marking one of India’s early public–private partnerships in CRISPR-based biotechnology. CrisprBits specialises in gene-editing platforms focused on developing cost-effective diagnostic and therapeutic solutions. The Centre of Excellence is envisioned as a bridge between fundamental research and clinical impact, combining JNCASR’s strengths in biomedical sciences with CrisprBits’ expertise in applied gene-editing and translational technologies. By addressing the long-standing gap between laboratory innovation and bedside application, the centre aims to demonstrate how Indian scientific research can be effectively transformed into societal and clinical benefits. It is also expected to serve as a replicable national model for strengthening collaboration between academia and industry within India’s biotechnology ecosystem. Commenting on the development, JNCASR President Umesh Waghmare said the partnership represents a landmark step for the institution, bringing together complementary capabilities in genetics, molecular and chemical biology, and computational biology. He added that the collaboration would open new pathways to deliver societal impact while contributing to national scientific and innovation missions.

Related Stories

Gold Stories

Next Story
Resources

Schindler named among Forbes’ World’s Best Employers 2026

Schindler has been named among Forbes’ World’s Best Employers 2026, a global ranking recognising companies for their workplace environments.Compiled by Forbes in partnership with Statista, the ranking is based on independent employee feedback, including whether employees would recommend their organisation to friends and family.The company said the recognition reflected its focus on creating a workplace where employees can develop their expertise and build careers. ..

Next Story
Infrastructure Urban

India needs an export-execution mindset: Vishesh Jain

Interview with Vishesh Jain, Founder & CEO, EximpleWhat gaps in India’s global trade ecosystem led you to build Eximple, and what problem did you see businesses struggling with most?Eximple came out of a problem that all three founders had seen from different choke points in the trade ecosystem. India has millions of MSMEs and manufacturers, and many of them can make products that are genuinely competitive on quality. Yet only a small fraction is able to build meaningful international businesses. In our experience, the gap is usually not manufacturing capability; it is the ability to exe..

Next Story
Building Material

Nuvoco reports 13.5% revenue growth in Q2 FY27

Nuvoco Vistas Corp. Ltd. reported consolidated revenue of Rs 27.9 billion for Q2 FY27, up 13.5% year on year. Cement sales volume rose 9% to 4.7 million tonnes (MMT), while EBITDA increased 11% to Rs 4.11 billion.The company said it began its cement operations in 2014 with a 2.3 MMT per annum (MMTPA) operation at Nimbol. It now aims to reach 35 MMTPA of cement capacity by FY28, nearly 15 times its initial capacity. Its portfolio spans cement, ready-mix concrete and modern building materials.On sustainability and cost efficiency, Nuvoco partnered with CleanMax for a 46.4 MW wind-solar hybrid re..

Advertisement

Subscribe to Our Newsletter

Get daily newsletters around different themes from Construction world.

STAY CONNECTED

Advertisement

SPECIAL OFFER
QR Code